Purpose
to development of a new safer Oral Polio Vaccine against type 2 strain (nOPV2) with lower risk of circulating vaccine derived polio virus (cVDVP) or vaccine associated paralytic poliomyelitis (VAPP) than existing Sabin mOPV 2
Grantee
Division
Global Development,
Global Health
Date
NOVEMBER 2014
Region served
GLOBAL
Committed amount
$3,081,165
Grant topic
Discovery and Translational Sciences,
Polio
Duration (months)
47
Grantee location
Bandung, Indonesia
Related work
More about our financials
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.